Xiao-qian Chen | pharmacology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Xiao-qian Chen | pharmacology | Best Researcher Award

Prof. Dr. Xiao-qian Chen, Huazhong University of Science and Technology, China.

Prof. Xiao Qian Chen 🧠 is a leading neurobiology and oncology researcher with over 25 high-impact publications 📚. As a Principal Investigator on 10+ national grants, he has pioneered studies on glioblastoma and neuroglobin. A professor since 2007, he’s received multiple awards 🏅 and holds a patent for neural therapy innovation. His international collaborations 🌍 and mentorship of young scientists 👨‍🔬 make him a driving force in translational brain research.

Profile

Scopus Profile

Orcid Profile

🎓 Early Academic Pursuits

Prof. Dr. Xiao Qian Chen embarked on his academic journey with a Bachelor of Medicine from Shanghai Medical University in 1988. He then pursued a Master’s in Medicine specializing in immunology at Peking Union Medical College and the Chinese Academy of Medical Sciences, graduating in 1997, followed by a Ph.D. in Biology from The Hong Kong University of Science and Technology in 2002. His foundational studies equipped him with a robust interdisciplinary grounding in medicine, immunology, and cutting-edge biological research. 🏛️

💼 Professional Endeavors

Following his Ph.D., Xiao Qian Chen served as an Engineer (1997–1999) at the Laboratory of Molecular Virology, CAS, Beijing. He transitioned to clinical work as a Surgeon (1988–1994) at Xi-Yuan Hospital, blending research with hands-on patient care. His postdoctoral stints included work at Peking University Neuroscience Research Institute (2002–2004) and as a Postdoc/Visiting Scholar (2010–2011) at Emory University’s Pharmacology Department. In academia, he rose from Associate Professor (2004–2007) to Professor from November 2007 at the Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan—where he continues to lead cutting-edge research.

🔬 Contributions and Research Focus On Pharmacology 

Prof. Chen’s research centers on neuroglobin biology, glioblastoma immunology, and neuronal survival under stress. As principal investigator, he has led over ten major projects funded by the National Natural Science Foundation of China, exploring mechanisms of glioma cytotoxicity, astrocyte transformation, and neuroprotection through signaling pathways (e.g., EGFR/PTEN/AKT/PD‑L1). Key themes include neuroglobin’s dual role in oxygen sensing and neuroprotection, and the therapeutic targeting of PD‑L1 and metabolic pathways in brain tumors.

🌍 Impact and Influence

Prof. Chen’s body of work has advanced understanding in both neurobiology and cancer biology. He has identified novel molecular targets such as neuroglobin and PD‑L1, elucidating their roles from neurite outgrowth and hypoxia responses to tumor immunity and chemoradiotherapy resistance. His integrative approach blends molecular experiments, in vivo models, and therapeutic studies, influencing subsequent research in glioblastoma treatment and neuroprotective strategies.

🧠 Research Skills

Prof. Chen’s methodology toolbox is robust and diverse:

  • Cell and molecular biology (protein interactions, gene expression)

  • Animal models (glioblastoma, ischemic stroke, autism, depression)

  • Neurochemistry & signaling assays (EGFR/PTEN/AKT, p38/JNK, autophagy pathways)

  • Immunology techniques (PD‑L1/PD‑1, microglia phenotyping, T‑cell infiltration)

  • Translational therapeutics, especially pharmacological modulation (e.g., Piperlongumine, CD73 inhibitors)

🏅 Awards and Honors

Prof. Chen’s excellence has been recognized through prestigious awards:

  • Second Prize, China Medical Science & Technology Award (2006) — for protective mechanisms in astrocytes during cerebral ischemia.

  • Second Prize, Hubei Science & Technology Progress Award (2019) — for work on Piperlongumamide in cancer treatment.

These accolades affirm the scientific and societal relevance of his discoveries.

🏛️ Legacy and Future Contributions

Prof. Chen’s enduring legacy lies in his cross-disciplinary integration of neuroscience and oncology, particularly in harnessing metabolic and immune modulation for disease intervention. Going forward, his ongoing grants (2022–2025) position him to lead breakthroughs in microglia reprogramming, astrocyte plasticity, and glioblastoma therapeutics. The translational promise of his research holds potential for neuroprotective and immunomodulatory therapies in serious CNS disorders.

Publications Top Notes

  1. 📘 Acta Pharmacologica Sinica (2025)
    Title: CD73 inhibitor AB680 suppresses glioblastoma in mice…
    📅 Year: 2025

  2. 🧠 Theranostics (2025)
    Title: A molecularly distinct cell type in the midbrain regulates intermale aggression…
    📅 Year: 2025

  3. 🧬 Journal of Experimental & Clinical Cancer Research (2023)
    Title: Piperlongumine conquers temozolomide chemoradiotherapy resistance…
    📅 Year: 2023

  4. 🧠 Neuroscience Bulletin (2023)
    Title: Neuroglobin Facilitates Neuronal Oxygenation through Tropic Migration…
    📅 Year: 2023

  5. 🧩 Molecular Neurobiology (2023)
    Title: KMT2E Haploinsufficiency Manifests Autism-Like Behaviors…
    📅 Year: 2023

  6. 🔬 Biochemical and Biophysical Research Communications (2021)
    Title: Rapid tumor recurrence in a novel murine GBM surgical model…
    📅 Year: 2021

  7. 🧪 Clinical and Translational Medicine (2020)
    Title: Mannose synergizes with chemoradiotherapy to cure cancer…
    📅 Year: 2020

  8. 🧠 Frontiers in Oncology (2019)
    Title: The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion…
    📅 Year: 2019

  9. 📡 Nature Communications (2019)
    Title: Locus coeruleus-CA1 projections are involved in chronic-depressive stress…
    📅 Year: 2019

  10. 🧫 Neurochemical Research (2019)
    Title: Selective 14-3-3γ Upregulation Promotes Beclin-1-LC3-Autophagic Influx…
    📅 Year: 2019

  11. 💊 Frontiers in Pharmacology (2019)
    Title: The prognostic and therapeutic value of PD-L1 in glioma
    📅 Year: 2019

  12. 🧬 Biochimica et Biophysica Acta – Molecular Basis of Disease (2018)
    Title: PD-L1 confers glioblastoma multiforme malignancy via Ras binding…
    📅 Year: 2018

  13. 🧠 Cell Death & Disease (2018)
    Title: Neuroglobin boosts axon regeneration during ischemic reperfusion…
    📅 Year: 2018

 

 

Xin Huang | Medicine | Best Researcher Award

Posted on by sciencefather

Prof. Xin Huang | Medicine | Best Researcher Award 

Prof. Xin Huang, Shanghai Jiaotong University School of Medicine Xinhua Hospital, China.

Professor Xin Huang 🧬 is a leading expert in reproductive medicine, specializing in PCOS molecular mechanisms. With over a decade of cutting-edge research, she has published in top journals and received numerous provincial and national awards 🏆. Her work bridges clinical practice and molecular biology, advancing embryo selection and fertility treatments 👩‍⚕️🧪. Professor Huang is also known for her strong interdisciplinary skills, securing multiple competitive research grants and contributing significantly to women’s health globally 🌍💡.

Profile

SCOPUS ID

🎓 Early Academic Pursuits

Prof. Xin Huang earned her Bachelor of Biology from Shandong University (1994–1998), followed by a Master’s in Biochemistry and Molecular Biology at Qingdao Agricultural University (2002–2005), and culminating in a PhD in the same field from Beijing Forestry University (2005–2008). These formative years provided her with a solid foundation in molecular techniques and research methodologies.

💼 Professional Endeavors

Teacher (1998–2002) — Educated high school students at No. 5 Middle School in Zibo, Shandong.

Embryologist (2008–2017) — Served at the Reproductive Medicine Centre, Yuhuangding Hospital, affiliated with Qingdao Medical University in Yantai.

Senior Embryologist & Professor (2017–present) — Leads embryology research and clinical efforts at the Department of Assisted Reproduction, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine.

🔬 Contributions and Research Focus On Medicine 

Since 2008, Professor Huang has focused on reproductive and endocrine disorders, notably polycystic ovary syndrome (PCOS). She pioneered the use of genome-wide microarrays to analyze gene expression in cumulus cells from PCOS patients, identifying key molecular pathways (e.g., Wnt, MAPK, calcium signaling) and biomarkers like LHCGR, TNIK, SOCS3, RUNX2, GPX3, PTX3. Her work extended into lncRNA and miRNA profiling, revealing regulatory molecules such as XLOC_011402 (PWRN2) and miR‑509‑3p that influence steroidogenesis and follicular microenvironment. She also explored follicular fluid metabolomics, using Raman spectroscopy to uncover metabolic signatures predictive of embryo quality and pregnancy outcomes

🌍 Impact and Influence

Professor Huang’s research offers key biomarkers for oocyte and embryo selection in IVF, especially for PCOS populations. Her findings have significantly advanced our understanding of oestradiol regulation, anovulation mechanisms, and the interplay between noncoding RNAs and metabolic pathways — shaping clinical strategies in assisted reproduction.

🧠 Research Skills

  • Embryology: IVF‑ET, ICSI, embryo & oocyte cryopreservation, PGD/PGS, FISH, assisted hatching, time‑lapse monitoring, spindle imaging, sperm viability assays.

  • Molecular Biology: Microarrays (cDNA, miRNA, lncRNA), gene cloning (RACE), vector design, protein assays (SDS‑PAGE, blots), qPCR, BiFC, yeast-two-hybrid, protein expression/purification, reporter assays, transformation techniques.

🏅 Awards and Honors

  • 2nd Prize, Yantai Sci/Tech Award (2014 & 2016)

  • 3rd Prize, Maternal & Child Health Award (2015 & 2017)

  • 2nd Prize, Shandong Medical Sci/Tech Award (2018)

  • 2nd Prize, Shandong Sci/Tech Progress Award (2019)
    These honors reflect sustained excellence in PCOS research and clinical translation.

🏛️ Legacy and Future Contributions

Professor Huang’s integrative approach—merging molecular biomarkers with clinical embryology—has already reshaped IVF strategies for PCOS patients. Her ongoing work in androgen-induced inflammasome activation (NLRP3 in microglia) and clinical metabolomic profiling promises to deepen understanding of PCOS-related comorbidities like depression and refine embryo selection methods. Her legacy is one of innovative translational research, fostering continued breakthroughs in reproductive endocrinology and assisted reproduction.

Publications Top Notes

  1. 📊 Frontiers in Cell and Developmental Biology (2021)
    Title: Raman spectrum of follicular fluid: a potential biomarker for oocyte developmental competence in PCOS
    Authors: Huang X#, Hong L#, Wu Y#, Chen M, Kong P, Ruan J, Teng X, Wei Z*

  2. 🧬 Aging (2020)
    Title: Depletion of exosomal circLDLR in follicle fluid derepresses miR-1294 function and inhibits estradiol production via CYP19A1 in PCOS
    Authors: Huang X#, Wu B#, Chen M#, Hong L, Kong P, Wei Z, Teng X*

  3. 🧪 European Journal of Obstetrics & Gynecology and Reproductive Biology (2020)
    Title: Systematic oxidative stress is not associated with live birth rate in young non-obese PCOS patients undergoing ART
    Authors: Chen M#, Huang X#, Liu Y, Lei S, Wu Y, Chen Z, Hong L, Teng X*

  4. 🧫 BMJ Open (2020)
    Title: Embryo incubation by time-lapse systems vs. conventional incubators in women with diminished ovarian reserve: protocol for RCT
    Authors: Chen M#, Wu Y#, Huang X#, et al.

  5. 🧠 Reproductive Biology and Endocrinology (2018)
    Title: lncRNA (PWRN2)-mediated ceRNA network in oocyte nuclear maturation in PCOS
    Authors: Huang X#, Pan J#, Wu B, Teng X

  6. 🧬 Reproduction (2016)
    Title: miRNA-509-3p promotes estradiol secretion by targeting MAP3K8 in cumulus cells of PCOS patients
    Authors: Huang X*, Liu C, Hao C, et al.

  7. 📚 Journal of Assisted Reproduction and Genetics (2016)
    Title: Aberrant expression of long noncoding RNAs in cumulus cells from PCOS patients
    Authors: Huang X*, Hao C*, Bao H, et al.

  8. 🧬 Reproduction (2013)
    Title: Transcriptional profiles of cumulus cells from MI and MII oocytes in PCOS patients
    Authors: Huang X, Hao C*, Shen X, et al.

  9. 🧬 Reproductive Biology and Endocrinology (2013)
    Title: RUNX2, GPX3, PTX3 gene expression in cumulus cells and embryo competence in PCOS
    Authors: Huang X, Hao C*, Shen X, et al.

  10. 🔥 Journal of Cellular and Molecular Medicine (2019)
    Title: S100‐A9 protein in exosomes from follicular fluid promotes inflammation via NF‐κB in PCOS
    Authors: Li H, Huang X, Chang X, et al.

  11. 🧠 Gynecological Endocrinology (2016)
    Title: GABAA receptor subunit expression in cumulus cells during oocyte maturation
    Authors: Dai H, Hao C*, Huang X, et al.

 

Lingzhi Zhong | Medicine | Best Researcher Award

Posted on by sciencefather

Dr. Lingzhi Zhong | Medicine | Best Researcher Award 

Dr. Lingzhi Zhong PLA General Hospital, China.

Dr. Lingzhi Zhong is an Assistant Research Fellow and Lecturer at the PLA General Hospital 🏥. She holds a Ph.D. in Pathology and Physiology from Jilin University 🎓. Her research specializes in tissue repair and regenerative medicine 🧬. With over ten peer-reviewed publications, several patents, and editorial roles, she has made remarkable strides in wound healing innovations 💡. Dr. Zhong is also a member of the Microcirculation Committee and continues to drive impactful biomedical research with passion and precision 🔬✨.

🌟 Professional Profile

Orcid Profile

🎓 Early Academic Pursuits

Lingzhi Zhong began her academic journey with a Ph.D. in Pathology and Physiology from Jilin University School of Basic Medicine. During her formative years, she cultivated a strong foundation in medical sciences, with a growing interest in tissue repair and regenerative medicine. Her rigorous academic training laid the groundwork for a prolific research career that would later evolve into impactful scientific contributions.

💼 Professional Endeavors

Dr. Zhong currently serves as an Assistant Research Fellow and Lecturer at the Department of Basic Medicine, PLA General Hospital. With over a decade of research experience, she is actively involved in the scientific community, both as a lecturer and investigator. Her professional trajectory also includes editorial roles, contributing as a board member and associate editor for esteemed academic publications. Her academic service underscores her dedication to both teaching and research leadership.

🔬 Contributions and Research Focus On Medicine 

Dr. Zhong’s research centers around wound healing, tissue regeneration, and anti-scarring innovations. One of her notable breakthroughs includes the reprogramming of fibroblasts into endothelial cells using forskolin, a discovery funded by the Youth Project of the National Natural Science Foundation of China. She has also explored the potential of arsenic compounds in inhibiting scar formation—an unprecedented approach in wound repair research. Her multi-faceted innovations bridge chemistry, biology, and medicine.

🌍 Impact and Influence

Her work has made a tangible impact on regenerative medicine, advancing strategies for scar reduction and chronic wound healing. The development of composite dressings and chitosan-based therapeutics reflects her commitment to clinical translation and improved patient outcomes. She has co-authored over ten SCI-indexed publications, each contributing to a better understanding of biological healing processes and therapeutic design.

🏆 Awards and Honors

Dr. Zhong has earned recognition for her pioneering research in regenerative medicine and wound care. Her nomination for the Best Researcher Award underlines her innovative edge and dedication to biomedical science. Her editorial appointments and participation in professional societies like the Microcirculation Committee of the Society of Integrated Traditional Chinese and Western Medicine further reinforce her respected standing in the scientific community.

📚 Books, Patents, and Innovation

Her contributions extend beyond journal articles. Dr. Zhong is currently co-authoring a book titled “Progress in Life Sciences”. She also holds three patents in advanced biomedical technologies:

  1. Composite dressing for skin healing

  2. Chemical induction of dermal fibroblasts

  3. Chitosan-taurine microbeads for scar reduction

These innovations demonstrate her translational research impact, turning lab discoveries into therapeutic applications.

🚀 Legacy and Future Contributions

Lingzhi Zhong is at the forefront of translational regenerative medicine. Her work continues to inspire new methods for scar-free healing, and she remains dedicated to developing novel bioactive delivery systems. With continued research, editorial leadership, and interdisciplinary collaboration, Dr. Zhong is poised to make lasting contributions to science and human health.

📚Publications Top Notes

  1. 🧴 Forskolin-loaded carboxymethyl chitosan and silk nanofiber hydrogels composite scaffolds improve skin regeneration
    International Journal of Biological Macromolecules, 2025

  2. 🧬 Chitosan-taurine nanoparticles cross-linked carboxymethyl chitosan hydrogels facilitate both acute and chronic diabetic wound healing
    International Journal of Biological Macromolecules, 2024

  3. 🧠 Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects
    Stem Cell Research & Therapy, 2022

  4. 🐷 Characterization of the Skin Bacteriome and Histology Changes in Diabetic Pigs
    The International Journal of Lower Extremity Wounds, 2022

  5. 🌿 Promotive effects of four herbal medicine ARCC on wound healing in mice and human
    Health Science Reports, 2022

  6. 🔬 A New Target of the Four-Herb Chinese Medicine for Wound Repair Promoted by Mitochondrial Metabolism Using Protein Acetylation Analysis
    Medical Science Monitor, 2022

  7. 🔥 Macrophage Related Chronic Inflammation in Non-Healing Wounds
    Frontiers in Immunology, 2021

  8. 🧫 Biological approaches for hypertrophic scars
    International Wound Journal, 2020

  9. 🩹 Chitosan/LiCl composite scaffolds promote skin regeneration in full-thickness loss
    Science China Life Sciences, 2020

  10. 🧪 Sustained release of inhibitor from bionic scaffolds for wound healing and functional regeneration
    Biomaterials Science, 2020

  11. 💧 Bioactive Molecules for Skin Repair and Regeneration: Progress and Perspectives
    Stem Cells International, 2019

  12. 🕸️ Concentrated Conditioned Medium-Loaded Silk Nanofiber Hydrogels with Sustained Release of Bioactive Factors To Improve Skin Regeneration
    ACS Applied Bio Materials, 2019

  13. 🚫 Arsenic trioxide inhibits the differentiation of fibroblasts to myofibroblasts through NFE2L2 and Smad2/3
    Journal of Cellular Physiology, 2019

  14. 🧪 Comparative Proteomic Analysis of the Effect of the Four-Herb Chinese Medicine ANBP on Promoting Mouse Skin Wound Healing
    The International Journal of Lower Extremity Wounds, 2017

  15. 🧠 Arsenic Trioxide Activate Transcription of Heme Oxygenase-1 via NFE2L2
    International Journal of Medical Sciences, 2015

  16. 🦴 Heme oxygenase-1 silencing increases sensitivity of osteosarcoma MG63 cells to arsenic trioxide
    Molecular and Cellular Biochemistry, 2014

Yuan Ma | Pharmacology | Best Researcher Award

Posted on by sciencefather

Dr. Yuan Ma | Pharmacology | Best Researcher Award 

Dr. Yuan Ma, Hong Kong Baptist University, Netherlands.

Ma Yuan (Ph.D.) is a Research Assistant Professor at the Institute for Precision Medicine and Innovative Drug, Hong Kong Baptist University. He specializes in aptamer-based translational research and drug discovery, with expertise in nucleic acid chemistry, advanced organic chemistry, and tumor pharmacology. Dr. Ma earned his Ph.D. from Peking University, focusing on nucleoside lipid delivery for oligonucleotides. With over 34 publications, his research has significantly advanced cancer therapeutics and targeted drug delivery. His work continues to shape innovative biomedical applications.

Professional Profile

Scopus Profile

Orcid Profile

🎓 Early Academic Pursuits

Ma Yuan demonstrated an early passion for pharmaceutical sciences, embarking on his academic journey at Peking University. He earned a Bachelor of Science (2009-2013), majoring in organic chemistry, pharmacology, and pharmaceutical analysis. Advancing his expertise, he pursued a Master of Science (2013-2015) at the Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University, focusing on DNA synthesis, medicinal chemistry, and tumor pharmacology. His master’s thesis explored the stability of D-/L-IsoNA modified siRNA under the mentorship of Prof. Zhenjun Yang. Driven by a deep interest in nucleic acid chemistry and drug development, Ma Yuan completed a Doctor of Philosophy (2015-2019) at the same institution, where he investigated novel nucleoside lipid delivery for single-stranded oligonucleotides, again under Prof. Zhenjun Yang.

💼 Professional Endeavors

Building on his strong academic foundation, Ma Yuan transitioned into cutting-edge research and drug discovery. His professional career began as an Associate Research Fellow (2019-2020) at the Mengchao Hepatobiliary Hospital of Fujian Medical University, where he focused on nucleic acid-based diagnostics and treatment for primary liver cancer. He then moved to Hong Kong Baptist University, serving as a Postdoctoral Research Fellow (2020-2022) and later as a Research Assistant Professor (2022-Present) at the Institute for Precision Medicine and Innovative Drug. His work in aptamer-based translational research and drug discovery has made significant contributions to the field of targeted therapy and precision medicine.

🔬 Contributions and Research Focus On Pharmacology 

Ma Yuan’s research is deeply embedded in the development of aptamer-based therapeutics, a revolutionary approach in cancer treatment and drug delivery. His work bridges organic chemistry, nucleic acid chemistry, and pharmacology, leading to breakthroughs in tumor-targeted therapies, nucleic acid-based drug modifications, and controlled drug release mechanisms. He has developed peptide aptamer-drug conjugates, explored hypoxia-potentiating agents, and innovated in bone anabolic aptamer therapies.

🌍 Impact and Influence

With a multidisciplinary approach spanning pharmaceutical chemistry, cancer therapy, and precision medicine, Ma Yuan’s research is shaping the future of personalized healthcare. His findings have contributed to improving drug efficacy, reducing side effects, and enhancing targeted delivery systems, significantly impacting the field of oncology and regenerative medicine.

📚 Academic Citations & Publications

Ma Yuan has authored over 34 research papers in high-impact journals, including Acta Materia Medica, Cancer Letters, Journal of Medicinal Chemistry, and Molecular Therapy Nucleic Acids. His work has been cited extensively, reinforcing his influence in the field of nucleic acid drug discovery. His contributions as a first author, co-first author, and corresponding author highlight his leadership in scientific research.

🏅 Awards and Honors

Throughout his career, Ma Yuan has received numerous accolades recognizing his excellence in pharmaceutical sciences and translational research. His research in aptamer-functionalized drug delivery systems and targeted cancer therapies has earned him global recognition.

🚀 Legacy and Future Contributions

As a pioneering researcher in nucleic acid-based therapies, Ma Yuan continues to push the boundaries of aptamer technology. His ongoing work in translational medicine, drug development, and biomolecular engineering promises to revolutionize cancer treatment, targeted drug delivery, and precision medicine. With his innovative approach and commitment to scientific advancement, he is set to leave a lasting impact on the future of personalized medicine.

Publications Top Notes

  1. Machine Learning-Powered, High-Affinity Modification Strategies for Aptamers 🧠🔬

    • Journal: Acta Materia Medica
    • Year: 2025 📅

  2. Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy 🎯💊

    • Journal: Pharmaceutics
    • Year: 2024 📅

  3. Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics 🦴🧬

    • Journal: Journal of Medicinal Chemistry
    • Year: 2024 📅

  4. Targeting Osteoblastic 11β-HSD1 to Combat High-Fat Diet-Induced Bone Loss and Obesity 🍔➡️🦴

    • Journal: Nature Communications
    • Year: 2024 📅

  5. Aptamer Functionalized Hypoxia-Potentiating Agent and Hypoxia-Inducible Factor Inhibitor Combined with Hypoxia-Activated Prodrug for Enhanced Tumor Therapy 🎯🦠

    • Journal: Cancer Letters
    • Year: 2024 📅

  6. Sclerostin Inhibition in Rare Bone Diseases 🦴💊

    • Journal: Journal of Orthopaedic Translation
    • Year: 2024 📅

  7. Advancing Targeted Combination Chemotherapy in Triple Negative Breast Cancer: Nucleolin Aptamer-Mediated Controlled Drug Release 🎯💊

    • Journal: Journal of Translational Medicine
    • Year: 2024 📅

  8. Small RNAs in Cancer Therapy 🧬🎗️

    • Book Chapter: Interdisciplinary Cancer Research
    • Year: 2024 📅

  9. Aptamer AS411 Interacts with the KRAS Promoter/hnRNP A1 Complex and Shows Increased Potency Against Drug-Resistant Lung Cancer 🫁💊

    • Journal: RSC Medicinal Chemistry
    • Year: 2024 📅

  10. Design and Synthesis of Nucleotidyl Lipids and Their Application in the Targeted Delivery of siG12D for Pancreatic Cancer Therapy 🎯🩸

  • Journal: Biomedicine and Pharmacotherapy
  • Year: 2024 📅
  1. Unique Quinoline Orientations Shape the Modified Aptamer to Sclerostin for Enhanced Binding Affinity and Bone Anabolic Potential 🦴🔬
  • Journal: Molecular Therapy – Nucleic Acids
  • Year: 2024 📅
  1. The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates 🧪🩺
  • Book Chapter: Drug Metabolism and Pharmacokinetics
  • Year: 2024 📅
  1. Intracellular Sclerostin Plays a Vital Role in Tumor Progression and Metastasis in Triple-Negative Breast Cancer 🎗️🦠
  • Journal: Cancer Research
  • Year: 2024 📅